학술논문
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
Document Type
Article
Author
Source
In The Lancet Diabetes & Endocrinology January 2021 9(1):22-31
Subject
Language
ISSN
2213-8587